SCHEMBL1099102

SCHEMBL1099102

Cc1cccc(CN(c2cc3ccccc3s2)S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MAPT P10636 3/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 3/20 0.43
NPSR1 Q6W5P4 2/20 0.42
TSHR P16473 1/20 0.42
CNR1 P21554 3/20 0.41
CNR2 P34972 3/20 0.41
GBA1 P04062 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
GLA P06280 1/20 0.40
NR3C1 P04150 1/20 0.40
APOBEC3A P31941 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
ACHE P22303 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1099311 0.89 ALDH1A1 (0.48) MEN1KMT2AL3MBTL1ALDH1A1LMNA
SCHEMBL1098989 0.86 MEN1 (0.64) TAS2R14MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL1099459 0.86 MEN1 (0.45) MEN1KMT2AL3MBTL1ALDH1A1LMNA
SCHEMBL1098229 0.85 PGR (0.53) TAS2R14MEN1KMT2AL3MBTL1MAPT
SCHEMBL1099002 0.82 PKM (0.50) MEN1KMT2AL3MBTL1MAPTALDH1A1
SCHEMBL1098896 0.81 MEN1 (0.45) TAS2R14MEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL1097602 0.81 PKM (0.54) TAS2R14MEN1KMT2AALDH1A1LMNA
SCHEMBL15948196 0.81 PKM (0.51) MEN1KMT2AL3MBTL1ALDH1A1KDM4E
SCHEMBL1097662 0.81 APOBEC3A (0.43) TAS2R14MEN1KMT2AMAPTALDH1A1
SCHEMBL1099967 0.81 NR3C1 (0.50) MEN1KMT2AL3MBTL1TRPM8NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TAS2R14 182/4885MEN1 1640/4885KMT2A 1231/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 TAS2R14 182/4885MEN1 1640/4885KMT2A 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.